nps-568 has been researched along with Kidney Failure, Chronic in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 13 (76.47) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caudrillier, A; Drüeke, TB; Fukagawa, M; Hamada, Y; Ivanovski, O; Joki, N; Kamel, S; Lacour, B; Maizel, J; Massy, ZA; Mentaverri, R; Nguyen-Khoa, T; Nikolov, IG; Phan, O | 1 |
| Davis, J; Fan, W; Florio, M; Fotsch, C; Henley, C; Lu, JY; Morony, S; Pretorius, JK; Reagan, JD; Richards, WG; Shatzen, E; St Jean, DJ; Sun, B; Yang, Y | 1 |
| Christopoulos, A; Conigrave, AD; Davey, AE; Leach, K; Sexton, PM; Valant, C | 1 |
| Goodman, WG; Turner, SA | 1 |
| Drüeke, TB | 1 |
| Frazão, JM; Ureña, P | 1 |
| Negri, AL; Slatopolsky, EA | 1 |
| Akizawa, T; Hatamura, I; Kinugasa, E; Koshikawa, S; Mizobuchi, M; Negi, S; Ogata, H; Saji, F; Sakaguchi, T; Shiizaki, K; Uda, S | 1 |
| Nagano, N; Nemeth, EF | 1 |
| Lindberg, JS | 1 |
| Cunningham, J | 1 |
| Dikow, R; Gross, ML; Ritz, E | 1 |
| Nagano, N | 1 |
| Andress, DL; Antonsen, JE; Sherrard, DJ | 1 |
| Nagano, N; Nemeth, EF; Wada, M | 1 |
| Coburn, JW; Frazao, JM; Goodkin, DA; Goodman, WG; Liu, W; Turner, SA | 1 |
| Lewin, E; Olgaard, K | 1 |
11 review(s) available for nps-568 and Kidney Failure, Chronic
| Article | Year |
|---|---|
Future role of calcimimetics in end-stage renal disease.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2002 |
Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Vitamin D | 2002 |
Calcimimetic agents: review and perspectives.
Topics: Aniline Compounds; Animals; Calcium; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2003 |
[Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Topics: Aniline Compounds; Animals; Bone Diseases; Calcium; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2003 |
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Models, Biological; Molecular Structure; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Receptors, Calcium-Sensing | 2005 |
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phenethylamines; Propylamines; Vitamin D | 2005 |
[Management of secondary hyperparathyroidism].
Topics: Aniline Compounds; Calcinosis; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phenethylamines; Phosphorus; Polyamines; Practice Guidelines as Topic; Propylamines; Receptors, Calcium-Sensing; Sevelamer; Vascular Diseases; Vitamin D | 2005 |
Role of calcium-phosphorous disorders in the progression of renal failure.
Topics: Aniline Compounds; Animals; Calcitriol; Calcium; Chronic Disease; Disease Progression; Fibroblast Growth Factor-23; Humans; Hypercalcemia; Hyperthyroidism; Kidney; Kidney Diseases; Kidney Failure, Chronic; Mesangial Cells; Parathyroid Hormone; Parathyroidectomy; Phenethylamines; Phosphates; Podocytes; Propylamines; Vitamin D | 2005 |
[Calcium receptor/calcium-sensing receptor].
Topics: Aniline Compounds; Binding Sites; Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Mutation; Naphthalenes; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Signal Transduction | 2006 |
The calcium receptor and calcimimetics.
Topics: Aniline Compounds; Animals; Bone Diseases; Calcium; Calcium-Binding Proteins; Drug Design; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Phenethylamines; Propylamines | 1999 |
Prevention of uremic bone disease using calcimimetic compounds.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface; Treatment Outcome; Uremia | 2001 |
1 trial(s) available for nps-568 and Kidney Failure, Chronic
| Article | Year |
|---|---|
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Topics: Adult; Aniline Compounds; Area Under Curve; Calcium; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phenethylamines; Propylamines | 2000 |
5 other study(ies) available for nps-568 and Kidney Failure, Chronic
| Article | Year |
|---|---|
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice.
Topics: Aniline Compounds; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Calcinosis; Calcium; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Kidney Failure, Chronic; Mice; Mice, Transgenic; Phenethylamines; Phosphorus; Propylamines; Receptors, Calcium-Sensing; Uremia | 2009 |
Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Topics: Aniline Compounds; Animals; Biphenyl Compounds; Calcitonin; Calcium; CHO Cells; Cricetinae; Cricetulus; Diethylamines; HEK293 Cells; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Inositol Phosphates; Kidney Failure, Chronic; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphorylation; Propylamines; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Dialysis | 2011 |
Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
Topics: Allosteric Site; Aniline Compounds; Calcimimetic Agents; Calcium; Cell Membrane; Cinacalcet; HEK293 Cells; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Failure, Chronic; Ligands; Naphthalenes; Phenethylamines; Phosphorylation; Propylamines; Receptors, Calcium-Sensing; Signal Transduction; Treatment Outcome | 2012 |
Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Topics: Analysis of Variance; Aniline Compounds; Animals; Base Sequence; Calcium; Disease Models, Animal; Gene Expression Regulation; Immunohistochemistry; Kidney Failure, Chronic; Male; Molecular Sequence Data; Nephrectomy; Parathyroid Glands; Phenethylamines; Probability; Propylamines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Up-Regulation | 2004 |
A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
Topics: Adult; Aged; Aniline Compounds; Calcitonin; Calcium; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phenethylamines; Propylamines | 1998 |